Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | CKS1B | P61024 | 2/20 | 0.54 |
| ▸ | SKP1 | P63208 | 2/20 | 0.54 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320120 | 0.86 | GPR119 (0.56) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL3782979 | 0.84 | MAP4K4 (0.61) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL31453948 | 0.84 | GPR119 (0.56) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL31704852 | 0.83 | GPR119 (0.53) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL15106095 | 0.82 | GPR119 (0.55) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL6975264 | 0.81 | GPR119 (0.54) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL26669193 | 0.81 | GPR119 (0.54) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL25329770 | 0.81 | MAP4K4 (0.55) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL30815767 | 0.81 | GPR119 (0.82) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL30493248 | 0.81 | MAP4K4 (0.55) | GPR119MAP4K4CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | GPR119 136/4885MAP4K4 1635/4885CKS1B 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.